OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma

December 12th 2022

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Dr Berdeja on the Safety and Efficacy of BMS-986393 in R/R Multiple Myeloma

December 11th 2022

Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.

Dr. Oliveira on the Examination of Camizestrant Vs Fulvestrant in ER+/HER2- Breast Cancer

December 9th 2022

Mafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.

Dr. Patel on Key Updates from First-Line Trials in NSCLC

December 9th 2022

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Dr. Verschraegen on the Need to Address TRAEs of Immunotherapy in Melanoma

December 9th 2022

Claire F. Verschraegen, MD, discusses the need to improve the management of treatment-related adverse effects of immunotherapy in melanoma.

Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC

December 9th 2022

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Dr. Sabari on the Importance of Timely Testing for Uncommon Mutations in NSCLC

December 9th 2022

Joshua K. Sabari, MD, discusses the importance of timely testing for uncommon mutations in non–small cell lung cancer.

Dr. Rohs on Databases of Uncommon Mutations in NSCLC

December 9th 2022

Nicholas C. Rohs, MD, discusses databases of uncommon mutations in non–small cell lung cancer

Dr. Mukherjee on the Implications of the FDA Approval of Second-line Liso-cel in LBCL

December 9th 2022

Akash Mukherjee, MD, discusses the implications of the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma.

Dr. Moroney on the Evaluation of COM701 Plus BMS-986207 and Nivolumab in Ovarian Cancer

December 9th 2022

John Moroney, MD, discusses the evaluation of COM701 plus BMS-986207 and nivolumab in platinum-resistant ovarian cancer.

Dr. Yeku on the Evaluation of COM701 Plus Nivolumab in Platinum-Resistant Ovarian Cancer

December 9th 2022

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.

Dr. Jacot on Ribociclib Dose Reduction in HR+/HER2– Advanced Breast Cancer

December 9th 2022

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

Dr. Hurvitz on Sequencing Therapeutic Options in HER2+ Breast Cancer

December 8th 2022

Sara A. Hurvitz, MD, discusses sequencing therapeutic options for patients with HER2-positive breast cancer.

Dr. Romancik on Maximizing CAR T-cell Therapy in NHL

December 8th 2022

Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Susanibar-Adaniya on the Impact of the MAIA and GRIFFIN Trials in Multiple Myeloma Treatment

December 8th 2022

Sandra P. Susanibar-Adaniya, MD, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Hurvitz on Trastuzumab Deruxtecan in Unresectable/Metastatic HER2+ Breast Cancer

December 7th 2022

Sara A. Hurvitz, MD, discusses updated survival data with fam-trastuzumab deruxtecan-nxki in HER2-positive, unresectable/metastatic breast cancer.

Dr. Abdou on Race and Clinical Outcomes in Breast Cancer

December 7th 2022

Yara Abdou, MD, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial.

Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

December 7th 2022

Ian Krop, MD, PhD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Dr. Patel on Adjuvant Nivolumab Plus Ipilimumab Regimens in Stage IV Melanoma

December 6th 2022

Sapna Patel, MD, discusses the evaluation of adjuvant nivolumab plus ipilimumab in stage IV metastatic melanoma with no evidence of disease.